MedTrace Logo

Trial of Vitamin D to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections

NCT04579640 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 6200

Last updated 2022-04-06

No results posted yet for this study

Summary

CORONAVIT is an open-label, phase 3, randomised clinical trial testing whether implementation of a test-and-treat approach to correction of sub-optimal vitamin D status results in reduced risk and/or severity of COVID-19 and other acute respiratory infections.

Conditions

  • Covid19
  • Acute Respiratory Tract Infection

Interventions

DIETARY_SUPPLEMENT

Vitamin D

Capsules containing 800 IU (20 micrograms) or 3,200 IU (80 micrograms) cholecalciferol

Sponsors & Collaborators

  • Barts & The London NHS Trust

    collaborator OTHER

  • Pharma Nord

    collaborator INDUSTRY

  • Fischer Family Trust

    collaborator UNKNOWN

  • The AIM Foundation

    collaborator UNKNOWN

  • Synergy Biologics Ltd

    collaborator UNKNOWN

  • Cytoplan Ltd

    collaborator UNKNOWN

  • Queen Mary University of London

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-27
Primary Completion
2021-06-17
Completion
2022-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04579640 on ClinicalTrials.gov